Baihua Pharmaceutical sees net sell-off of 313.37 million yuan after hitting daily limit on Shanghai exchange
Baihua Pharmaceutical (600721) experienced extreme volatility on the Shanghai Stock Exchange from September 22-24, hitting its daily price limit on September 22 with a 50.63% turnover rate, then falling 8.15% on September 23. Brokerage desks recorded net sell-offs each day, totaling 313.37 million yuan on September 22, 45.28 million yuan on September 23, and 41.7 million yuan on September 24. The company's semi-annual report showed revenue down 22.13% and net profit down 42.08%.
IllustrationEditorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page reads the event directly, while its address stays stable when the title changes.
- Summary covers the current reports
Cross-source coverage
Common ground
- Baihua Medicine is a bad investment right now due to declining revenue and profit.
- The Dragon and Tiger list provides useful transparency about who is trading.
- Retail investors should not buy this stock based on the data.
- The 46% single-day turnover is excessive and a red flag.
Points of contention
- Whether the speculation in Baihua signals a systemic failure in China's market or just normal market behavior.
- Whether the Dragon and Tiger list transparency makes the market fair or just reveals an unfair game.
- Whether the net selling by brokerages is a healthy self-correction or a coordinated exit by informed players.
- Whether comparing Baihua to US meme stocks like GameStop is a valid defense or a distraction.
Blind spots
- The 24-hour gap between when informed traders see order flow and when retail sees it is a key source of unfairness.
- Both sides focus on the stock or the system, but ignore how retail investors are influenced by hype and social media.
- The debate overlooks whether regulators should step in to limit extreme turnover rates, not just flag them.
WorldAttention’s read
The roundtable agrees that Baihua Medicine is a speculative trap with weak fundamentals and that the Dragon and Tiger list offers rare transparency. However, they disagree on whether this is a normal market event or a sign of deeper problems. The main blind spot is the information gap that lets informed traders profit before retail sees the data. Ultimately, the smart money is selling, and retail buyers should stay away — but this single stock doesn't prove China's whole market is broken.
Reporting timeline
Baihua Medicine's top-traded stock sees net sell-off of 41.7 million yuan
According to data from the Shanghai Stock Exchange, Baihua Medicine (百花医药) appeared on the 'Dragon and Tiger List' on September 24 due to a daily turnover rate of 39.69%. The top five buying and selling brokerage departments combined for a total turnover of 499 million yuan, with buy-side transactions at 229 million yuan and sell-side at 270 million yuan, resulting in a net sell-off of 41.7 million yuan. The largest buyer and seller was Guotai Haitong Securities. Over the past six months, the stock has appeared on the list 31 times, with an average price increase of 0.74% the day after listing and 1.08% after five days. On the day, the stock saw a net inflow of 41.4 million yuan from major funds, including 42.5 million yuan from very large orders. The company's semi-annual report released on August 25 showed a 22.13% year-on-year decline in revenue to 157 million yuan and a 42.08% drop in net profit to 14.76 million yuan.
Baihua Medicine sees 46.10% turnover rate, net sell by brokerage seats totals 45.28 million yuan
According to public information from the Shanghai Stock Exchange, Baihua Medicine (百花医药) appeared on the Dragon and Tiger list on September 23 due to a daily turnover rate of 46.10%. Brokerage seats on the list recorded a total net sell of 45.277 million yuan. Data from Securities Times and DataBao shows that the top five buying and selling brokerage seats had a combined turnover of 581 million yuan, with buy-side transactions at 268 million yuan and sell-side at 313 million yuan, resulting in a net sell of 45.277 million yuan. Over the past six months, the stock has appeared on the Dragon and Tiger list 30 times, with an average price increase of 0.86% on the day after listing and 1.51% five days after. On the day, the stock saw a net outflow of main capital of 120 million yuan, including 66.8733 million yuan from super-large orders and 53.354 million yuan from large orders. Over the past five days, main capital saw a net inflow of 596 million yuan. The company's semi-annual report released on August 25 showed that in the first half of the year, it achieved total operating revenue of 157 million yuan, down 22.13% year-on-year, and net profit of 14.7603 million yuan, down 42.08% year-on-year.
Read sourceBaihua Pharma turnover 46.10%, brokerage seats net sell 45.28 million yuan
Baihua Pharmaceutical (600721) fell 8.15% on September 23, with a turnover rate of 46.10% and trading volume of 2.422 billion yuan. According to Shanghai Stock Exchange data, the stock was listed on the dragon and tiger board due to the high turnover, with brokerage seats net selling 45.277 million yuan. The top five buying and selling seats had a total turnover of 581 million yuan, with buying at 268 million yuan and selling at 313 million yuan. The top buying seat was Guotai Haitong Securities headquarters with 105.1368 million yuan, while the top selling seat was Goldman Sachs (China) Securities Shanghai Pudong Century Avenue branch with 91.3892 million yuan. Over the past six months, the stock has appeared on the dragon and tiger board 30 times, with an average gain of 0.86% the next trading day and 1.51% after five days. Main capital saw a net outflow of 120 million yuan. The company's half-year report on August 25 showed revenue of 157 million yuan, down 22.13% year-on-year, and net profit of 14.7603 million yuan, down 42.08%.
Read sourceShow 2 older updatesHide older updates
Baihua Pharmaceutical Hits Daily Limit, Net Sell by Brokerage Departments Reaches 313.37 Million Yuan
Baihua Pharmaceutical (600721) hit its daily price limit on September 22, with a turnover rate of 50.63% and total trading volume of 2.739 billion yuan. According to the Shanghai Stock Exchange's public data, the stock was flagged for a daily price deviation of 9.98% and high turnover. Brokerage departments on the Dragon and Tiger list recorded a net sell of 313.37 million yuan. The top five buy and sell departments combined for 7.03 billion yuan in transactions, with buys at 3.50 billion yuan and sells at 3.53 billion yuan. The largest buy and sell department was Goldman Sachs (China) Securities' Shanghai Pudong Century Avenue branch, with buys of 93.5794 million yuan and sells of 89.0433 million yuan. Over the past six months, the stock has appeared on the Dragon and Tiger list 29 times, with an average gain of 1.19% the next trading day and 2.52% after five days. Main capital saw a net inflow of 204 million yuan on the day, with large orders contributing 185 million yuan. The company's semi-annual report released on August 25 showed revenue of 157 million yuan in the first half, down 22.13% year-on-year, and net profit of 14.7603 million yuan, down 42.08%.
Baihua Medicine hits daily limit-up; brokerage desks net sell 313.37 million yuan
Baihua Medicine (百花医药) hit the daily price limit-up on September 22, triggering a disclosure on the Shanghai Stock Exchange due to a 9.98% daily price deviation and a 50.63% turnover rate. According to Securities Times data, the top five buying and selling brokerage desks had a total turnover of 7.03 billion yuan, with buy orders at 3.50 billion yuan and sell orders at 3.53 billion yuan, resulting in a net sell of 313.37 million yuan. Goldman Sachs (China) Securities' Shanghai Century Avenue branch was both the top buyer (93.58 million yuan) and top seller (89.04 million yuan). Over the past six months, the stock has appeared on the dragon and tiger list 29 times, with an average gain of 1.19% the next trading day and 2.52% after five days. Main capital saw a net inflow of 2.04 billion yuan on the day, including 1.85 billion yuan from super-large orders. However, the company's half-year report released on August 25 showed revenue of 157 million yuan, down 22.13% year-on-year, and net profit of 14.76 million yuan, down 42.08% year-on-year.
Read source